This site is intended for health professionals only!

Published on 28 July 2009

Share this story:

Good first six months in 2009 for Boehringer Ingelheim

teaser

The pharmaceutical company Boehringer Ingelheim again posted gratifying growth in local currency (+8.3 percent) over the previous year in the first six months of 2009. Consolidated in euro, this reflected growth of + 15.7 percent thanks to the positive exchange rates, with net sales of EUR 6,388 million compared with EUR 5,522 million in the first six months of the previous year.

The operating income developed equally well over the previous year. Currency effects played their part here, too, adding to the positive development of the individual businesses.

In the first six months, net sales of Boehringer Ingelheim again outpaced the growth on the world pharma market.

Prof. Dr Dr Andreas Barner, Chairman of the Board of Managing Directors: “We have posted growth in our business areas Human Pharmaceuticals, thanks in particular to the success of our innovative prescription medicines, and in Animal Health, thanks to the growth in the segment of vaccines. Despite the negative impact in some areas as a result of the financial crisis, local business development in the first half of 2009 shows that Boehringer Ingelheim is maintaining its growth course, virtually unchanged, and continues to outpace the pharmaceutical market,” said Andreas Barner.

Boehringer Ingelheim is again expecting sales growth in local currency in the year as a whole to outpace the world pharma market; for the tenth time in succession. Growth in euro depends greatly on the exchange rate trends of the US dollar and the Japanese yen.

Due to important patent expiries, for instance for the drug FLOMAX® in the USA, Boehringer Ingelheim in 2010 is likely to see virtually no significant growth after ten years. Yet already in 2011 a new period of growth will be heralded from new innovative medications, which already will be introduced in 2010. These launches will trigger additional investments in 2010.

In the first six months of 2009, net sales in our core Prescription Medicines business rose to EUR 5,107 million, signifying growth of +9.1 percent in local currency (+17.3 percent in euro).



Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story: